Molecular tools: Biology, prognosis, and therapeutic triage

Neuroimaging Clinics of North America

Volumn 20, Issue 3, 2010, Pages 273-282

  Fischer, Ingeborg ^a,b   Aldape, Kenneth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Genetic; Glioma; Malignant tumor; Molecular; Targeted therapy

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VATALANIB;

ANGIOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC ANALYSIS; GLIOBLASTOMA; GLIOMA; HIGH THROUGHPUT SCREENING; HUMAN; NEUROSURGERY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE THERAPY;

ADULT; BRAIN NEOPLASMS; CELL PROLIFERATION; GLIOMA; HUMANS; MOLECULAR BIOLOGY; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955583321     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2010.05.004     Document Type: Review

References (91)

1. Okamoto Y., Di Patre P.L., Burkhard C., et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004, 108(1):49-56.
2. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64(6):479-489.
3. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005, 25(1):1-7.
4. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64(19):6892-6899.
5. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170(5):1445-1453.
6. Wolter M., Reifenberger J., Blaschke B., et al. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 2001, 60(12):1170-1180.
7. Perry A., Miller R., Guirati M., et al. Malignant gliomas with neuroblastic (PNET-like) components (GBM-PNET): a clinicopathologic and genetic study of 28 cases. Neuro Oncol 2007, 9(4):543.
8. Houillier C., Lejeune J., Benouaich-Amiel A., et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006, 106(10):2218-2223.
9. Griffin C.A., Burger P., Morsberger L., et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006, 65(10):988-994.
10. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90(19):1473-1479.
11. Kros J.M., Gorlia T., Kouwenhoven M.C., et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007, 66(6):545-551.
12. van den Bent M.J. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 2007, 25(4):1089-1099. ix-x.
13. Aldape K., Burger P.C., Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007, 131(2):242-251.
14. Van Den Bent M.J. Guidelines for the treatment of oligodendroglioma: an evidence-based medicine approach. Forum (Genova) 2003, 13(1):18-31.
15. Weller M., Berger H., Hartmann C., et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?. Clin Cancer Res 2007, 13(23):6933-6937.
16. Abrey L.E., Louis D.N., Paleologos N., et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007, 9(3):314-318.
17. Sasaki H., Zlatescu M.C., Betensky R.A., et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001, 159(1):359-367.
18. Chan A.S., Leung S.Y., Wong M.P., et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998, 22(7):816-826.
19. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773.
20. Guha A., Dashner K., Black P.M., et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 1995, 60(2):168-173.
21. Maher P.A. Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 1996, 134(2):529-536.
22. Hermanson M., Funa K., Hartman M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52(11):3213-3219.
23. Dunn I.F., Heese O., Black P.M. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000, 50(1-2):121-137.
24. Savage D.G., Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002, 346(9):683-693.
25. Haberler C., Gelpi E., Marosi C., et al. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 2006, 76(2):105-109.
26. von Deimling A., von Ammon K., Schoenfeld D., et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993, 3(1):19-26.
27. Fischer I., de la Cruz C., Rivera A.L., et al. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). Diagn Mol Pathol 2008, 17(4):227-230.
28. Tripp S.R., Willmore-Payne C., Layfield L.J. Relationship between EGFR overexpression and gene amplification status in central nervous system gliomas. Anal Quant Cytol Histol 2005, 27(2):71-78.
29. Ekstrand A.J., Longo N., Hamid M.L., et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994, 9(8):2313-2320.
30. Lal A., Glazer C.A., Martinson H.M., et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002, 62(12):3335-3339.
31. Pelloski C.E., Ballman K.V., Furth A.F., et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007, 25(16):2288-2294.
32. Jungbluth A.A., Stockert E., Huang H.J., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003, 100(2):639-644.
33. Belda-Iniesta C., Carpeno Jde C., Saenz E.C., et al. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 2006, 5(8):912-914.
34. Haas-Kogan D.A., Prados M.D., Lamborn K.R., et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005, 4(10):1369-1372.
35. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97(12):880-887.
36. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353(19):2012-2024.
37. Platten M., Wick W., Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001, 52(4):401-410.
38. Yamada N., Kato M., Yamashita H., et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995, 62(4):386-392.
39. Wick W., Platten M., Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 2001, 53(2):177-185.
40. Lamouille S., Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007, 178(3):437-451.
41. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24(37):5764-5774.
42. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9(3):157-173.
43. Schlingensiepen K.H., Schlingensiepen R., Steinbrecher A., et al. Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006, 17(1-2):129-139.
44. Shnaper S., Desbaillets I., Brown D.A., et al. Elevated levels of MIC-1/GDF15 in the cerebro-spinal fluid (CSF) of patients are associated with glioblastoma and worse outcome. Int J Cancer 2009, 125(11):2624-2630.
45. Jeuken J.W., van der Maazen R.W., Wesseling P. Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Tech Canc Res Treat 2006, 5(3):215-229.
46. Knobbe C.B., Reifenberger J., Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004, 108(6):467-470.
47. Cloughesy T.F., Wen P.Y., Robins H.I., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006, 24(22):3651-3656.
48. Moyal E.C., Laprie A., Delannes M., et al. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2007, 68(5):1396-1401.
49. Chakravarti A., Zhai G., Suzuki Y., et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004, 22(10):1926-1933.
50. Knobbe C.B., Merlo A., Reifenberger G. Pten signaling in gliomas. Neuro Oncol 2002, 4(3):196-211.
51. Knobbe C.B., Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003, 13(4):507-518.
52. Fan Q.W., Knight Z.A., Goldenberg D.D., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9(5):341-349.
53. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294-5304.
54. Aktas H., Cai H., Cooper G.M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol 1997, 17(7):3850-3857.
55. Reifenberger G., Ichimura K., Reifenberger J., et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996, 56(22):5141-5145.
56. Reifenberger G., Reifenberger J., Ichimura K., et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994, 54(16):4299-4303.
57. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366(6456):704-707.
58. Ueki K., Ono Y., Henson J.W., et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996, 56(1):150-153.
59. Yin D., Zhou H., Kumagai T., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24(3):344-354.
60. Kubicek G.J., Werner-Wasik M., Machtay M., et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009, 74(2):433-439.
61. Hupp T.R., Lane D.P., Ball K.L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000, 352(Pt 1):1-17.
62. Lang F.F., Bruner J.M., Fuller G.N., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003, 21(13):2508-2518.
63. Brat D.J., Castellano-Sanchez A.A., Hunter S.B., et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004, 64(3):920-927.
64. Cheng S.Y., Huang H.J., Nagane M., et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996, 93(16):8502-8507.
65. Fischer I., Gagner J.P., Law M., et al. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005, 15(4):297-310.
66. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
67. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729.
68. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745.
69. Quant E.C., Norden A.D., Drappatz J., et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009, 11(5):550-555.
70. Kubo K., Shimizu T., Ohyama S., et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem 2005, 48(5):1359-1366.
71. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
72. de Bouard S., Herlin P., Christensen J.G., et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007, 9(4):412-423.
73. Reardon D.A., Egorin M.J., Desjardins A., et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009, 115(10):2188-2198.
74. Gladson C.L. The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 1999, 58(10):1029-1040.
75. Tonn J.C., Wunderlich S., Kerkau S., et al. Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 1998, 18(4A):2599-2605.
76. Taga T., Suzuki A., Gonzalez-Gomez I., et al. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002, 98(5):690-697.
77. Reardon D.A., Fink K.L., Mikkelsen T., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26(34):5610-5617.
78. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003, 3(7):489-501.
79. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004, 70(2):217-228.
80. Wang M., Wang T., Liu S., et al. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003, 20(2):65-72.
81. Yamamoto M., Sawaya R., Mohanam S., et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994, 54(14):3656-3661.
82. Groves M.D., Puduvalli V.K., Conrad C.A., et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 2006, 80(1):83-90.
83. Joy A.M., Beaudry C.E., Tran N.L., et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003, 116(Pt 21):4409-4417.
84. Koul D., Shen R., Bergh S., et al. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 2006, 5(3):637-644.
85. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10(6):1871-1874.
86. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
87. Freije W.A., Castro-Vargas F.E., Fang Z., et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64(18):6503-6510.
88. Li A., Walling J., Ahn S., et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009, 69(5):2091-2099.
89. Nigro J.M., Misra A., Zhang L., et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005, 65(5):1678-1686.
90. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110.
91. Noushmehr H., Weisenberger D.J., Diefes K., et al. Identification of a Cpg island methylator phenotype that defines a distinct subgroup of Glioma. Cancer Cell 2010, 17(5):510-522.